本文選題：冠心病 + 內(nèi)皮損傷　； 參考：《遼寧中醫(yī)藥大學(xué)》2017年碩士論文

【摘要】：目的:本研究依據(jù)“內(nèi)皮損傷學(xué)說”,通過血清藥理學(xué)實(shí)驗(yàn),探究中藥對內(nèi)皮細(xì)胞和級聯(lián)反應(yīng)細(xì)胞干擾素的影響,為科研與臨床驗(yàn)證中藥治療冠心病療效提供候選檢測方法。方法:1選取健康受試者10例,臨床劑量靜點(diǎn)舒血寧注射液,進(jìn)行安全性臨床觀察,同時(shí)制備含藥血清。2制作內(nèi)皮細(xì)胞PAF損傷模型,以空白和含藥血清培養(yǎng)細(xì)胞,觀察細(xì)胞形態(tài)與增殖,以Elisa試劑盒檢測細(xì)胞上清分泌物中NO、VE-Ca、ICAM-1、VCAM-1濃度,觀察舒血寧對細(xì)胞及級聯(lián)反應(yīng)細(xì)胞干擾因素的影響,研究其對冠心病內(nèi)皮損傷的干預(yù)作用。結(jié)果:1舒血寧注射液臨床試驗(yàn)觀察,受試者前后生命體征、肝腎功、血常規(guī)、凝血五項(xiàng)中,體溫、淋巴細(xì)胞、中性粒細(xì)胞P值0.05,考慮為樣本量過少所致;余項(xiàng)P值均0.05,表明用藥前后無明顯變化。不良反應(yīng)1例,1級輕度,可能與試驗(yàn)藥物無關(guān)。2造模:當(dāng)以濃度為25umol/L的PAF作用4h后,細(xì)胞存活率平均值為47.45±6.95,細(xì)胞損傷率近50%,考慮為理想造模條件。細(xì)胞增殖隨PAF濃度的升高、誘導(dǎo)時(shí)間的延長而受到抑制程度也加重,PAF誘導(dǎo)細(xì)胞損傷。3與模型對照組相比,含藥血清組細(xì)胞形態(tài)生長狀態(tài)良好,增殖72.9%±4.87%,NO濃度下降,VE-Ca、ICAM-1、VCAM-1濃度升高,與空白對照組相近,與模型對照組存在明顯差異。結(jié)論1舒血寧注射液能夠通過改善細(xì)胞形態(tài),促進(jìn)細(xì)胞增殖,調(diào)節(jié)細(xì)胞分泌功能,對內(nèi)皮細(xì)胞和細(xì)胞級聯(lián)反應(yīng)干擾素產(chǎn)生影響。2以人體血清及細(xì)胞實(shí)驗(yàn)為依托的中藥治療冠心病療效的候選檢測方法具有可行性。
[Abstract]:Objective: To investigate the effect of Chinese medicine on the interferon in endothelial cells and cascade reaction cells through the theory of "endothelial injury", and to provide a candidate detection method for the therapeutic effect of Chinese medicine in the treatment of coronary heart disease by scientific research and clinical validation. 1 the clinical dose of Shuxuening injection was carried out in 10 healthy subjects. The PAF damage model of endothelial cells was prepared by the preparation of.2 containing serum, and the cell morphology and proliferation were observed with blank and drug containing serum. The concentration of NO, VE-Ca, ICAM-1 and VCAM-1 in the secretions of cell supernatant was detected by Elisa kit, and the effects of Shuxuening on the cell and cascade reaction cells were observed. The interventional effect of endothelium injury in coronary heart disease. Results: 1 the clinical trial of Shuxuening injection was observed in the clinical trial. In the subjects, the body temperature, the liver and kidney work, the blood routine and the coagulation five, the body temperature, the lymphocyte and the P value of neutrophils were 0.05, and the value of the remainder P was 0.05, indicating that there were no obvious changes before and after the drug use, 1 cases of adverse reactions and 1 light weight. Degree, may be irrelevant to the test drug.2 model: when the concentration of 25umol/L PAF action 4h, the average cell survival rate is 47.45 + 6.95, the cell damage rate is nearly 50%, considered as the ideal modeling condition. Cell proliferation with the increase of PAF concentration, the prolongation of induction time and the increase of inhibition range, PAF induced cell injury.3 and model control group In contrast, the cell morphologic growth of the serum containing drug group was 72.9% + 4.87%, the concentration of NO decreased, the concentration of VE-Ca, ICAM-1 and VCAM-1 increased, which was similar to that of the blank control group, and there was significant difference between the control group and the model control group. Conclusion 1 Shuxuening Injection can improve the cell morphology, promote the cell proliferation, regulate the cell secretion function, and the endothelial cells and the endothelial cells. Cell cascade reaction interferon production affects.2. It is feasible to detect human coronary heart disease with Chinese medicine based on human serum and cell experiments.

【學(xué)位授予單位】：遼寧中醫(yī)藥大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R259

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 劉欣,石應(yīng)康,祝彼得;培養(yǎng)內(nèi)皮細(xì)胞的分化[J];生物醫(yī)學(xué)工程學(xué)雜志;1999年02期

2 衛(wèi)朝霞,劉永波;一種新的內(nèi)皮細(xì)胞分離方法[J];河南職工醫(yī)學(xué)院學(xué)報(bào);2003年03期

3 任德成;胡娟娟;張均田;杜冠華;;血管內(nèi)皮細(xì)胞損傷機(jī)制研究[J];醫(yī)學(xué)研究通訊;2003年10期

4 潘虹;王庭槐;;內(nèi)皮細(xì)胞caveolae,caveolin-1的生理功能[J];醫(yī)學(xué)綜述;2006年22期

5 殷觀梅;;血管內(nèi)皮細(xì)胞生長抑制因子研究進(jìn)展[J];河北醫(yī)藥;2008年12期

6 劉寶宜,陳鐵鎮(zhèn),張寶庚,宋繼業(yè);動(dòng)脈粥樣硬化形成過程中內(nèi)皮細(xì)胞病變的研究(摘要)——主動(dòng)脈內(nèi)皮細(xì)胞平掙,掃描電鏡及透射電鏡的觀察[J];中國醫(yī)科大學(xué)學(xué)報(bào);1981年S1期

7 劉寶宜,陳鐵鎮(zhèn),張寶庚,宋繼業(yè);動(dòng)脈粥樣硬化形成過程中內(nèi)皮細(xì)胞的形態(tài)學(xué)變化的研究(主動(dòng)脈內(nèi)皮細(xì)胞平鋪技術(shù),掃描電鏡及透射電鏡的方法)[J];中國醫(yī)科大學(xué)學(xué)報(bào);1982年03期

8 張連元;;動(dòng)脈粥樣硬化發(fā)病機(jī)理中平滑肌和內(nèi)皮細(xì)胞的機(jī)能[J];煤礦醫(yī)學(xué);1983年04期

9 劉懷瓊;李德馨;;內(nèi)皮細(xì)胞的功能與休克的關(guān)系[J];國外醫(yī)學(xué).麻醉學(xué)與復(fù)蘇分冊;1985年04期

10 何澤涌;;關(guān)于內(nèi)皮細(xì)胞研究的某些進(jìn)展[J];山西醫(yī)藥雜志;1987年03期

相關(guān)會(huì)議論文 前10條

1 應(yīng)大君;陳衛(wèi)軍;周丁華;;內(nèi)皮細(xì)胞機(jī)械感受功能的實(shí)驗(yàn)研究[A];面向21世紀(jì)的科技進(jìn)步與社會(huì)經(jīng)濟(jì)發(fā)展（下冊）[C];1999年

2 鄧紅;李懿萍;來茂德;;高糖環(huán)境細(xì)胞間相互作用對內(nèi)皮細(xì)胞產(chǎn)生活性氧和血管內(nèi)皮細(xì)胞生長因子的影響[A];中華醫(yī)學(xué)會(huì)病理學(xué)分會(huì)2005年學(xué)術(shù)年會(huì)論文匯編[C];2005年

3 林萍章;PualJ.Pearson;RaymondCartier;KazuhiroHashimoto;HartzellV.Schaff;;內(nèi)膜再生過程中,內(nèi)皮細(xì)胞之反應(yīng)[A];海峽兩岸電子顯微學(xué)討論會(huì)論文專集[C];1991年

4 趙彭濤;李志超;董明清;賈斌;張莉莉;;LPS對培養(yǎng)的BPAECsⅠ型Na~+/H~+交換器活性的影響[A];第六次全國缺氧和呼吸病理生理學(xué)術(shù)會(huì)議論文摘要匯編[C];2003年

5 熊建瓊;朱佩芳;王正國;蔣建新;;髓樣分化蛋白-2在內(nèi)毒素與內(nèi)皮細(xì)胞結(jié)合中的作用[A];第十一次全國急診醫(yī)學(xué)學(xué)術(shù)會(huì)議暨中華醫(yī)學(xué)會(huì)急診醫(yī)學(xué)分會(huì)成立二十周年慶典論文匯編[C];2006年

6 邴雅s，

本文編號(hào)：1838247